RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma
Status:
Terminated
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial is studying the side effects and the best dose of RO4929097 to see how
well it works when given together with bevacizumab compared to bevacizumab alone in treating
patients with progressive or recurrent malignant glioma. RO4929097 may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies,
such as bevacizumab, can block tumor growth in different ways. Some block the ability of
tumor cells to grow and spread. Others find tumor cells and help kill them or carry
tumor-killing substances to them. Giving RO4929097 together with bevacizumab may kill more
tumor cells.